IM Cannabis Looks To Expand Operations Into US After Trump's Executive Order

IM Cannabis is assessing entry into the U.S. cannabis market following President Trump's December 18 executive order directing the Attorney General to expedite rescheduling marijuana from Schedule I to Schedule III. The company has retained SSC Advisors to provide financial and strategic guidance, including identifying potential U.S. partners or acquirors. The move reflects a potential material expansion of IMCC's addressable market contingent on regulatory change and transaction execution; IMCC shares traded pre-market at $1.51, up 9.42% on the Nasdaq.

Analysis

Winners will be US multi-state operators (CURLF, GTBIF, TRUL) and nimble Canadian LPs with US-facing management (IMCC) because rescheduling to Schedule III materially reduces banking and custody frictions and raises M&A optionality; losers include smaller Canadian-only cultivators (high cash burn) and black-market suppliers if tax/price structures normalize. Competitive dynamics favor well-capitalized MSOs that can scale retail footprint and wholesale distribution; expect market share consolidation with top 5 MSOs capturing +10–20 percentage-point share over 12–36 months, pressuring marginal small producers and compressing spot wholesale prices 10–30% in saturated states.

Tail risks: DEA/DOJ could delay or reissue restrictive rules, Congress could negate changes, or Treasury/Fed guidance could lag, producing 30–60% drawdowns in equity prices; operational risks include cross-border licensing, 280E tax ambiguity, and near-term equity dilution as companies raise capital—watch for >10% share issuance. Timeline: immediate (days) = sentiment spike; short-term (1–6 months) = M&A/partnership announcements and volatility; long-term (1–3 years) = durable demand expansion and margin normalization.

Trade implications: favored plays are concentrated, size-limited longs in IMCC (speculative US entry), diversified long exposure to CURLF/GTBIF, and buy-call-spreads to cap premium; pair trades can pair long high-quality US MSO vs short high-burn Canadian LP (e.g., long GTBIF, short ACB) to hedge policy risk. Key catalysts to trade around: DEA final rule, Fed/Treasury banking guidance, SSC Advisors-led M&A announcements—use 3–9 month option durations to capture policy windows.

Contrarian view: market is underpricing dilution and execution risk—small caps like IMCC may need >$20–50M financing within 6–12 months, which would dilute existing equity 10–30%; rescheduling does not automatically remove 280E or create IMF-level banking access, so upside is conditional and likely asymmetric. Historical parallels (state-by-state legalization waves) show multi-year rollouts; therefore avoid paying full valuations for immediate national legalization narratives.

Key Decisions for Investors

• Consider establishing a 2–3% long position in IM Cannabis (IMCC) sized for high-risk/high-reward exposure; target +40–60% upside on a confirmed US market entry or strategic partner within 6–12 months, with a hard stop-loss at -35% or on any announced equity raise >10% of market cap.
• Initiate 1–2% long positions each in Curaleaf (CURLF) and Green Thumb (GTBIF) to capture consolidation; target 18–36 month total returns of 50%+, trim 25% on a 30% rally, and reduce if DEA/Fed guidance is not issued within 90 days.
• Buy 3–9 month call spreads on CURLF (buy 25% OTM calls, sell 40% OTM calls) sized at 0.5–1% notional to play policy-driven volatility while capping premium; roll or take profits if DEA publishes final rule or if IV compresses >30%.
• Implement a market-neutral pair trade: long GTBIF (1% notional) and short Aurora Cannabis (ACB, 1% notional) to express quality differential; unwind after 6–12 months or on material regulatory clarity (DEA final rule or federal banking guidance) or if spread narrows <10% from initial entry.